Hoban Katie A, Downie Samantha, Adamson Douglas J A, MacLean James G, Cool Paul, Jariwala Arpit C
NHS Tayside, Ninewells Hospital & Medical School, Dundee, United Kingdom.
NHS Tayside, Perth Royal Infirmary, Perth, United Kingdom.
JSES Int. 2022 Apr 25;6(4):675-681. doi: 10.1016/j.jseint.2022.03.006. eCollection 2022 Jul.
The aim of this study was to investigate the reproducibility, reliability, and accuracy of Mirels' score in upper limb bony metastatic disease and validate its use in predicting pathologic fractures.
Forty-five patients with upper limb bony metastases met the inclusion criteria (62% male 28/45). The mean age was 69 years (SD 9.5), and the most common primaries were lung (29%, 13/45), followed by prostate and hematological (each 20%, 9/45). The most commonly affected bone was the humerus (76%, 35/45), followed by the ulna (6.5%, 3/45). Mirels' score was calculated in 32 patients; with plain radiographs at index presentation scored using Mirels' system by 6 raters. The radiological aspects (lesion size and appearance) were scored twice by each rater (2 weeks apart). Intraobserver and interobserver reliability were calculated using Fleiss' kappa test. Bland-Altman plots compared the variances of both individual components and the total Mirels' score.
The overall fracture rate of upper limb metastatic lesions was 76% (35/46) with a mean follow-up of 3.6 years (range 11 months-6.8 years). Where time from diagnosis to fracture was known (n = 20), fractures occurred at a median 19 days (interquartile range 60-10), and 80% (16/20) occurred within 3 months of diagnosis.Mirels' score of ≥9 did not accurately predict lesions that fractured (fracture rate 11%, 5/46, for Mirels' ≥ 9 vs. 65%, 30/46, for Mirels' ≤ 8, < .001). Sensitivity was 14%, and specificity was 73%. When Mirels' cutoff was lowered to ≥7, patients were more likely to fracture than not (48%, 22/46, vs. 28%, 13/46, = .045); sensitivity rose to 63%, but specificity fell to 55%.Kappa values for interobserver variability were κ = 0.358 (fair, 95% confidence interval [CI] 0.288-0.429) for lesion size, κ = 0.107 (poor, 95% CI 0.02-0.193) for radiological appearance, and κ = 0.274 (fair, 95% CI 0.229-0.318) for total Mirels' score. Values for intraobserver variability were κ = 0.716 (good, 95% CI 0.432-0.999) for lesion size, κ = 0.427 (moderate, 95% CI 0.195-0.768) for radiological appearance, and κ = 0.580 (moderate, 95% CI 0.395-0.765) for total Mirels' score.
This study demonstrates moderate to substantial agreement between and within raters using Mirels' score on upper limb radiographs. However, Mirels' score had a poor sensitivity and specificity in predicting upper extremity fractures. Until a more valid scoring system has been developed, based on our study, we recommend a Mirels' threshold of ≥7/12 for considering prophylactic fixation of impending upper limb pathologic fractures. This contrasts with the current ≥9/12 cutoff, which is recommended for lower limb pathologic fractures.
本研究的目的是调查米雷尔斯评分在上肢骨转移性疾病中的可重复性、可靠性和准确性,并验证其在预测病理性骨折方面的应用。
45例上肢骨转移患者符合纳入标准(男性占62%,28/45)。平均年龄为69岁(标准差9.5),最常见的原发肿瘤是肺癌(29%,13/45),其次是前列腺癌和血液系统肿瘤(各占20%,9/45)。最常受累的骨骼是肱骨(76%,35/45),其次是尺骨(6.5%,3/45)。对32例患者计算米雷尔斯评分;6名评估者使用米雷尔斯系统对初次就诊时的X线平片进行评分。每位评估者对放射学特征(病变大小和外观)进行两次评分(间隔2周)。使用弗莱iss卡方检验计算观察者间和观察者内的可靠性。采用布兰德-奥特曼图比较各个组成部分和米雷尔斯总分的差异。
上肢转移性病变的总体骨折率为76%(35/46),平均随访3.6年(范围11个月至6.8年)。在已知从诊断到骨折时间的患者中(n = 20),骨折发生的中位时间为19天(四分位间距60 - 10),80%(16/20)的骨折发生在诊断后3个月内。米雷尔斯评分≥9并不能准确预测发生骨折的病变(米雷尔斯评分≥9时骨折率为11%,5/46;米雷尔斯评分≤8时骨折率为65%,30/46;P <.001)。敏感性为14%,特异性为73%。当米雷尔斯评分的临界值降至≥7时,患者发生骨折的可能性大于未发生骨折的可能性(48%,22/46,对比28%,13/46;P = .045);敏感性升至63%,但特异性降至55%。观察者间病变大小的卡方值κ = 0.358(一般,95%置信区间[CI] 0.288 - 0.429),放射学外观的κ = 0.107(较差,95% CI 0.02 - 0.193),米雷尔斯总分的κ = 0.274(一般,95% CI 0.229 - 0.318)。观察者内病变大小的卡方值κ = 0.716(良好,95% CI 0.432 - 0.999),放射学外观的κ = 0.427(中等,95% CI 0.195 - 0.768),米雷尔斯总分的κ = 0.580(中等,95% CI 0.395 - 0.765)。
本研究表明,评估者之间以及评估者内部使用米雷尔斯评分对上肢X线平片的评估具有中度到高度的一致性。然而,米雷尔斯评分在预测上肢骨折方面的敏感性和特异性较差。在开发出更有效的评分系统之前,基于本研究,我们建议对于即将发生的上肢病理性骨折,考虑预防性固定时米雷尔斯评分的阈值为≥7/12。这与目前推荐用于下肢病理性骨折的≥9/12临界值不同。